Kevin Tabury
Program Pipeline Manager - Head of Innovation & Translational Development Unit Belgian Nuclear Research Center
Seminars
Tuesday 1st December 2026
From FAP to B7-H3: What Determines Whether a Radiopharmaceutical Target Successfully Translates to the Clinic?
11:30 am
- Identifying the key biological, translational and clinical characteristics that differentiate high-potential radiopharmaceutical targets from those unlikely to succeed
- Exploring how target expression, tumour microenvironment interactions and biomarker strategies influence development decisions
- Understanding the role of preclinical modelling, radiobiology and imaging in strengthening confidence before clinical translation
Tuesday 1st December 2026
Beyond Tumour Uptake: Building the Right In Vivo Models for Radiopharmaceutical Translation
2:30 pm
- Understanding why target expression and tumour uptake alone are insufficient to predict radiopharmaceutical efficacy, toxicity and clinical success
- Exploring how tumour biology, heterogeneity, target accessibility and tumour microenvironment influence radiopharmaceutical distribution and, critically, the absorbed dose delivered to tumour and healthy organs
- Identifying the characteristics of fit-for-purpose in vivo models that enable integrated assessment of biodistribution, dosimetry, imaging, radiobiological response and therapeutic window, strengthening candidate selection and confidence in clinical translation
